Literature DB >> 30417262

Prognosis associated with synchronous or metachronous multiple primary malignancies in patients with completely resected non-small cell lung cancer.

Hiroaki Komatsu1, Nobuhiro Izumi2, Takuma Tsukioka2, Hidetoshi Inoue2, Kantaro Hara2, Hikaru Miyamoto2, Noritoshi Nishiyama2.   

Abstract

PURPOSE: To investigate the influence of multiple primary malignancies (MPMs) on the prognosis of patients with completely resected non-small cell lung cancer (NSCLC).
METHODS: The subjects of this retrospective study were 521 patients who underwent complete curative pulmonary resection for NSCLC. Patients were divided into two groups: those with and those without MPMs.
RESULTS: The 521 NSCLC patients included 184 patients (35.3%) with MPMs and 337 patients without MPMs. The overall 5-year survival rates for patients with vs those without MPMs were 66.1 and 75.6%, respectively (p = 0.0061). According to multivariate analysis, MPMs, age, gender, pathological stage, and interstitial pneumonia were independent predictors of prognosis. The 47 patients with synchronous MPMs and the 82 patients with metachronous MPMs found within the last 5 years had significantly poorer prognoses than patients without MPMs (p = 0.0048 and p = 0.0051, respectively). However, the prognoses of the 55 patients with metachronous MPMs that had been present for over 5 years did not differ from those of the patients without MPMs.
CONCLUSIONS: NSCLC patients with synchronous MPMs or metachronous MPMs diagnosed within the last 5 years had poor prognoses. Decisions about the best therapeutic strategies require comprehensive consideration of the organ location, malignant potential, recurrence, and prognosis of the MPMs. In contrast, decisions about the best therapeutic strategies for NSCLC patients with metachronous MPMs present for over 5 years should be based solely on the NSCLC.

Entities:  

Keywords:  Multiple primary malignancies; Non-small cell lung cancer; Surgery

Mesh:

Year:  2018        PMID: 30417262     DOI: 10.1007/s00595-018-1738-4

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  6 in total

1.  Prevalence of lung tumors in patients with esophageal squamous cell carcinoma and vice versa: a systematic review and meta-analysis.

Authors:  Laurelle van Tilburg; Steffi E M van de Ven; Manon C W Spaander; Laurens A van Kleef; Robin Cornelissen; Marco J Bruno; Arjun D Koch
Journal:  J Cancer Res Clin Oncol       Date:  2022-06-23       Impact factor: 4.553

2.  Correction of the tumor suppressor Salvador homolog-1 deficiency in tumors by lycorine as a new strategy in lung cancer therapy.

Authors:  Zhe Zhao; Shufen Xiang; Jindan Qi; Yijun Wei; Mengli Zhang; Jun Yao; Tong Zhang; Mei Meng; Xiaohua Wang; Quansheng Zhou
Journal:  Cell Death Dis       Date:  2020-05-21       Impact factor: 8.469

3.  Preoperative virtual simulation for synchronous multiple primary lung cancers using three-dimensional computed tomography lung reconstruction: a case report.

Authors:  Weichun Wu; Yimin Wu; Gang Shen; Guofei Zhang
Journal:  J Cardiothorac Surg       Date:  2021-01-07       Impact factor: 1.637

4.  A Descriptive Study of the Types and Survival Patterns of Saudi Patients with Multiple Primary Solid Malignancies: A 30-Year Tertiary Care Center Experience.

Authors:  Moustafa S Alhamadh; Rakan B Alanazi; Sultan T Algarni; Ahmed Abdullah R Alhuntushi; Mohammed Qasim Alshehri; Yusra Sajid Chachar; Mohammad Alkaiyat; Fouad Sabatin
Journal:  Curr Oncol       Date:  2022-07-13       Impact factor: 3.109

5.  The CT delta-radiomics based machine learning approach in evaluating multiple primary lung adenocarcinoma.

Authors:  Yanqing Ma; Jie Li; Xiren Xu; Yang Zhang; Yi Lin
Journal:  BMC Cancer       Date:  2022-09-03       Impact factor: 4.638

6.  Synchronous Primary Lung Adenocarcinoma and Hepatocellular Carcinoma Successfully Treated with a Combination of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel.

Authors:  Takashi Egawa; Keita Masuzawa; Sohei Nakayama; Ichiro Maeda; Satoshi Tsunematsu; Yukio Suzuki; Yusuke Suzuki
Journal:  Intern Med       Date:  2021-04-12       Impact factor: 1.271

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.